Protective effects of thymol against nephrotoxicity induced by cisplatin with using 99mTc-DMSA in mice

Renal Failure

Volumn 37, Issue 2, 2015, Pages 280-284

  Hosseinimehr, Seyed Jalal ^a   Asadian, Reza ^a   Naghshvar, Farshad ^a   Azizi, Soheil ^a   Jafarinejad, Mehdi ^a   Noaparast, Zohreh ^a   Abedi, Seyed Mohammad ^a   Hosseini, Seyed Amir Hossein ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc DMSA; Kidney; Nephrotoxicity; Renoprotective; Thymol

Indexed keywords

CISPLATIN; SUCCIMER TC 99M; THYMOL; ALKYLATING AGENT; ANTIOXIDANT; CREATININE; PROTECTIVE AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; KIDNEY PARENCHYMA; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RENAL PROTECTION; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; KIDNEY; KIDNEY DISEASES; PATHOPHYSIOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; CISPLATIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; KIDNEY DISEASES; MALE; MICE; PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; THYMOL; TREATMENT OUTCOME;

EID: 84923164105     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.991998     Document Type: Article

References (41)

1. Fruscio R, Garbi A, Parma G, et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J Natl Cancer Inst. 2011;103(4):347-351.
2. Gupta S, Khan H, Barik S, Negi MP. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer. Drug Discov Ther. 2013;7(1):36-42.
3. Stathopoulos GP, Trafalis D, Dimitroulis J, Kosmas C, Stathopoulos J, Tsavdaridis D. Combination of three cytotoxic agents in small-cell lung cancer. Cancer Chemother Pharmacol. 2013;71(2):413-418.
4. Wang J, Liu F, Huang DX, Jiang B. Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: A clinical prospective analysis of 451 patients. Asian Pac J Cancer Prev. 2012;13(9):4505-4510.
5. Burch PA, Richardson RL, Cha SS, et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol. 2000;164(5):1538-1542.
6. Arunkumar P, Viswanatha G, Radheshyam N, Mukund H, Belliyappa M. Science behind cisplatin-induced nephrotoxicity in humans: A clinical study. Asian Pac J Trop Biomed. 2012; 2(8):640-644.
7. Dekkers IA, Blijdorp K, Cransberg K, et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol. 2013;8(6):922-929.
8. Sancho-Martinez SM, Prieto-Garcia L, Prieto M, Lopez-Novoa JM, Lopez-Hernandez FJ. Subcellular targets of cisplatin cytotoxicity: An integrated view. Pharmacol Ther. 2012;136(1):35-55.
9. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007.
10. Fillastre JP, Raguenez-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett. 1989;46(1-3):163-175.
11. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci. 2007;334(2):115-124.
12. Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant. 1997;12(12):2478-2480.
13. Sajed H, Sahebkar A, Iranshahi M. Zataria multiflora Boiss. (Shirazi thyme) - An ancient condiment with modern pharmaceutical uses. J Ethnopharmacol. 2013;145(3):686-698.
14. Schmidt E, Wanner J, Hiiferl M, et al. Chemical composition, olfactory analysis and antibacterial activity of Thymus vulgaris chemotypes geraniol, 4-thujanol/terpinen-4-ol, thymol and linalool cultivated in southern France. Nat Prod Commun. 2012; 7(8):1095-1098.
15. Hosseinimehr SJ, Mahmoudzadeh A, Ahmadi A, Ashrafi SA, Shafaghati N, Hedayati N. The radioprotective effect of Zataria multiflora against genotoxicity induced by γ irradiation in human blood lymphocytes. Cancer Biother Radiopharm. 2011; 26(3):325-329.
16. Azuma Y, Ozasa N, Ueda Y, Takagi N. Pharmacological studies on the anti-inflammatory action of phenolic compounds. J Dent Res. 1986;65(1):53-56.
17. Alam K, Nagi MN, Badary OA, Al-Shabanah OA, Al-Rikabi AC, Al-Bekairi AM. The protective action of thymol against carbon tetrachloride hepatotoxicity in mice. Pharmacol Res. 1999; 40(2):159-163.
18. Archana PR, Nageshwar Rao B, Satish Rao BS. In vivo radio-protective potential of thymol, a monoterpene phenol derivative of cymene. Mutat Res. 2011;726(2):136-145.
19. Al-Malki AL. Antioxidant properties of thymol and butylated hydroxytoluene in carbon tetrachloride-induced mice liver injury. JKAU: Sci. 2010;22(1):239-248.
20. Kruk I, Michalska T, Lichszteld K, Kladna A, Aboul-Enein HY. The effect of thymol and its derivatives on reactions generating reactive oxygen species. Chemosphere. 2000;41(7):1059-1064.
21. Weyer K, Nielsen R, Petersen SV, Christensen EI, Rehling M, Birn H. Renal uptake of 99mTc-dimercaptosuccinic acid is dependent on normal proximal tubule receptor-mediated endocytosis. J Nucl Med. 2013;54(1):159-165.
22. Muller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m-DMSA. J Nucl Med. 1995;36(9):1654-1658.
23. Caglar M, Yaris N, Akyuz C. The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity. Nucl Med Commun. 2001;22(12):1325-1332.
24. Yurekli Y, Unak P, Yenisey C, Ertay T, Biber Muftuler FZ, Medine EI. L-carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Mol Imaging Radionucl Ther. 2011;20(1):1-6.
25. Cabuk M, Gurel A, Sen F, Demircan N. Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: A comparison of 99mTc-DMSA uptake with biochemical studies. Mol Cell Biochem. 2008;308(1-2):35-42.
26. Yigit MV, Mazumdar D, Kim HK, Lee JH, Odintsov B, Lu Y. Smart "turn-on" magnetic resonance contrast agents based on aptamer-functionalized superparamagnetic iron oxide nanoparticles. Chembiochem. 2007;8(14):1675-1678.
27. Shimeda Y, Hirotani Y, Akimoto Y, et al. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005;28(9):1635-1638.
28. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol. 2008;28(3):337-344.
29. Pratibha R, Sameer R, Rataboli PV, Bhiwgade DA, Dhume CY. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur J Pharmacol. 2006;532(3):290-293.
30. Mohan IK, Khan M, Shobha JC, et al. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats. Cancer Chemother Pharmacol. 2006;58(6):802-808.
31. Miyawaki Y, Ueki M, Ueno M, Asaga T, Tokuda M, Shirakami G. D-allose ameliorates cisplatin-induced nephrotoxicity in mice. Tohoku J Exp Med. 2012;228(3):215-221.
32. Nozaki Y, Kinoshita K, Yano T, et al. Signaling through the interleukin-18 receptor alpha attenuates inflammation in cisplatin-induced acute kidney injury. Kidney Int. 2012;82(8):892-902.
33. Domitrovic R, Cvijanovic O, Pugel EP, Zagorac GB, Mahmutefendic H, Skoda M. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology. 2013;310:115-123.
34. Ku CM, Lin JY. Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1/Th2 cytokine secretion profiles using murine primary splenocytes. Food Chem. 2013; 141(2):1104-1113.
35. Liu Y, Webb HK, Fukushima H, et al. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling. J Pharmacol Exp Ther. 2012;341(3):725-734.
36. Sahu BD, Kuncha M, Sindhura GJ, Sistla R. Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine. 2013; 20(5):453-460.
37. Sultana S, Verma K, Khan R. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress. J Pharm Pharmacol. 2012;64(6):872-881.
38. Fachini-Queiroz FC, Kummer R, Estevao-Silva CF, et al. Effects of thymol and carvacrol, constituents of Thymus vulgaris L. essential oil, on the inflammatory response. Evid Based Complement Alternat Med. 2012;2012:657026.
39. Riella KR, Marinho RR, Santos JS, et al. Anti-inflammatory and cicatrizing activities of thymol, a monoterpene of the essential oil from Lippia gracilis, in rodents. J Ethnopharmacol. 2012; 143(2):656-663.
40. Braga PC, Dal Sasso M, Culici M, Bianchi T, Bordoni L, Marabini L. Anti-inflammatory activity of thymol: Inhibitory effect on the release of human neutrophil elastase. Pharmacology. 2006;77(3):130-136.
41. Liang D, Li F, Fu Y, et al. Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-kappaB and MAPK signaling pathways in mouse mammary epithelial cells. Inflammation. 2014;37(1):214-222.